Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer

Related articles

1. Novel antibody cocktail therapy targeting extracellular tumor-specific mutations to treat triple-negative breast cancer

   This article has 10 authors:

   1. Stephanie C. Pero
   2. Girja S. Shukla
   3. Yujing Sun
   4. Ramiro Barrantes-Reynolds
   5. Colin J. Hartman
   6. Margaret E. Ackerman
   7. Linda Mei
   8. Fan Zhang
   9. Matthew R. Fournier
   10. David N. Krag

2. PRC2 loss impairs small cell lung cancer tumorigenesis and enhances sensitivity to G9a/GLP inhibition

   This article has 12 authors:

   1. Maarten van Lohuizen
   2. Jawahar Kopparam
   3. Gayathri Chandrasekaran
   4. Danielle Hulsman
   5. Liesa-Marie Pilger
   6. Karen Stevers
   7. Ji-Ying Song
   8. Miguel Hernandez-Quiles
   9. Jelmer Dijkstra
   10. Nick Landman
   11. Michiel Vermeulen
   12. Jitendra Badhai

3. A selective inhibitor of oncogenic JNK signalling perturbs metastatic outgrowth of triple-negative breast cancer through metabolic blockade

   This article has 40 authors:

   1. Sharissa L Latham
   2. Yolande EI O’Donnell
   3. Oscar Girgis-Cook
   4. Misaki S Clearwater
   5. Nicole S Bryce
   6. Ellie TY Mok
   7. Sophie A Lynn
   8. Jenny Ni
   9. Stephanie Alfred
   10. King Ho Leong
   11. Lake-ee Quek
   12. Kendelle J Murphy
   13. Chiara Pantarelli
   14. Iliya Dragutinovic
   15. Marjan M Naeini
   16. Claudia Thiel
   17. Antonia Cadell
   18. Monica Phimmachanh
   19. Rashmi Sharma
   20. Ewan Millar
   21. Jeremy ZR Han
   22. Jordan F Hastings
   23. Martin Köhler
   24. Tilman Brummer
   25. Adelaide Young
   26. Sandra O’Toole
   27. Samantha R Oakes
   28. Edna Hardeman
   29. John Lock
   30. Walter Kolch
   31. Manuel H Taft
   32. Max Nobis
   33. Leonard Goldstein
   34. Paul Timpson
   35. Benjamin L Parker
   36. Jeff Holst
   37. Peter W Gunning
   38. Thomas R Cox
   39. Jonathan C Morris
   40. David R Croucher